Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1843 results
February 2018
-
Media Release
Treatment with Novartis' Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflation
Ultibro® Breezhaler® provided significant improvements in cardiac and lung function in COPD patients with lung hyperinflation, compared to placebo CLAIM is the first study to… -
Media Release
AveXis to Report Fourth Quarter and Full Year 2017 Financial and Operating Results
Conference call and webcast on February 27 at 4:30 p.m. EST CHICAGO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments… -
Media Release
Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis
Two thirds of patients on Cosentyx® (secukinumab) reported no impact of skin disease on their quality of life over 5 years, SCULPTURE study shows[1] Findings show absolute PASI <=1/… -
Media Release
Novartis new Cosentyx® data confirms robust efficacy and quality of life improvements in scalp psoriasis
Majority of patients with scalp psoriasis on Cosentyx® (secukinumab) achieved clear skin (PSSI 90) at Weeks 12 and 24 and improved quality of life[1] Scalp psoriasis affects 60 million… -
Media Release
Novartis forms alliance to develop medicines for treating infectious diarrheal disease
Novartis receives funding from Bill & Melinda Gates Foundation for further development of Novartis drug candidate KDU731 for the treatment of cryptosporidiosis Cryptosporidiosis is the… -
Media Release
Sandoz announces US FDA approval and launch of Glatopa® 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis
Glatopa® 40 mg/mL is a fully substitutable, AP-rated generic version of Copaxone®* (glatiramer acetate injection) 40 mg/mL Glatopa 40 mg/mL, along with Glatopa® 20 mg/mL, which was launched… -
Potential weight loss treatment takes shape with help from patients
Novartis researchers are partnering with advocacy groups to understand the stigma and challenges facing patients with obesity.
-
Media Release
Novartis receives FDA approval for Cosentyx® label update to include moderate-to-severe scalp psoriasis
US label updated to include Cosentyx® (secukinumab) data in moderate-to-severe scalp psoriasis[1] - one of the difficult-to-treat types of psoriasis[2] Approximately half of all 125 million… -
Compound designed to fight Alzheimer’s disease shows promise in the lab
The molecule restores the activity of neurons and neural circuits in a model of the disease.
-
Partnering for improved cancer care around the globe
Novartis works tirelessly with third-party organizations to improve access to cancer care.
-
Living with breast cancer in Uganda
Suzan Akello describes what life has been like since her cancer diagnosis.
-
Key Release
Novartis completes subsequent offering period of the tender offer for Advanced Accelerator Applications S.A.
Basel, February 1, 2018 - Novartis AG (NYSE: NVS) today announced the completion of the subsequent offering period of the tender offer by its subsidiary, Novartis Groupe France S.A., to purchase all…
Pagination
- ‹ Previous page
- 1
- …
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- …
- 154
- › Next page
Test disclaimer...!!!